Antheia: Valuation, Funding & Investors
Antheia is a pharmaceutical ingredient manufacturer focused on transforming essential medicine supply chains through its advanced biomanufacturing platform. The company is committed to commercializing a diverse pipeline of over 70 biosynthetic pharmaceutical ingredients across seven therapeutic areas, prioritizing essential medicines that are in or at risk of shortage. Antheia aims to enhance domestic manufacturing capabilities and expand its strategic innovation programs into Asia.
Leadership & Board
- Current Number of Employees
- 71
- Current LinkedIn Followers
- 10,431
Latest Estimated Valuation
- Total Amount Raised
- $160M
- Total Funding Rounds
- 3
- Latest Funding Amount
- $80M
- Latest Funding Round
- Investment
Company Momentum Positive
Antheia LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Antheia had 71 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Antheia had 10,431 followers as of October 26, 2026. The number of followers increased by 108 (1.05%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 18, 2026 | Investment | $80.00M | ― |
| Jan 27, 2026 | Series C | $24.00M | ― |
| Jun 03, 2025 | Series C | $56.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| U.S. Department of War's Office of Strategic Capital | Investment |
| EDBI | Series C |
| America's Frontier Fund | Series C |
| ATHOS KG | Series C |
| Global Health Investment Corporation | Series C |
Similar Companies
A snapshot of private companies similar to Antheia, helping you discover and navigate related company profiles.
